Press Release
OVN Staff
The Authority Company | Breaking Silos in Oncology
Summary
In this episode of The Authority Company Podcast, host Joe Pardavila sits down with Dr. Ramin Farhood and Dr. Kirk Shepard, co-authors of Voices of Oncology and co-founders of the Medical Affairs Professional Society (MAPS). Together, they share how breaking down silos, fostering collaboration, and elevating the patient voice are reshaping the future of oncology drug development. Farhood and Shepard reflect on their decade-long partnership in oncology, the lessons learned from working across functions, and why they believe true progress depends on bringing every perspective to the table—from scientists and regulators to patients and advocates. They discuss the “moonshot” mindset, the surprising insights from more than 30 contributors to their book, and how advances in AI and real-time FDA review processes are accelerating the path from research to treatment. This conversation highlights the optimism, challenges, and collaborative breakthroughs driving innovation in cancer care—and why building a global community of experts is essential to finding cures.
Podcast
Watch on YouTube
Joe Pardavila sits down with Dr. Ramin Farhood and Dr. Kirk Shepard to discuss breaking down silos, fostering collaboration, and elevating the patient voice are reshaping the future of oncology drug development.
Related Topics
You May Also Like
OVN Staff
Press Release
OVN Staff
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
Press Release
OVN Staff
Introducing OncologyVoiceNetwork.com
Article
Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
Article
R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
Article
Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles